JP7768880B2 - Ｅｚｈ２を阻害するためのキノリン化合物および組成物 - Google Patents

Ｅｚｈ２を阻害するためのキノリン化合物および組成物

Info

Publication number
JP7768880B2
JP7768880B2 JP2022530800A JP2022530800A JP7768880B2 JP 7768880 B2 JP7768880 B2 JP 7768880B2 JP 2022530800 A JP2022530800 A JP 2022530800A JP 2022530800 A JP2022530800 A JP 2022530800A JP 7768880 B2 JP7768880 B2 JP 7768880B2
Authority
JP
Japan
Prior art keywords
amino
methyl
chloro
methylquinolin
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022530800A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538159A (ja
JP2023538159A5 (https=
Inventor
ダイ，シュアン
ドーレ，マイケル
グー，シャンジュ，ジャスティン
リー，リン
チン リウ，クン
イェウン，フランキー マク，シン
ミ，ユアン
オヤン，カウンド
パピヨン，ジュリエン
キー，ウェイ
ヤン，シャオシャオ
ユ，チェンティアン
ユー チャン，ジ
ザオ，キハオ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2023538159A publication Critical patent/JP2023538159A/ja
Publication of JP2023538159A5 publication Critical patent/JP2023538159A5/ja
Application granted granted Critical
Publication of JP7768880B2 publication Critical patent/JP7768880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022530800A 2020-08-10 2021-08-10 Ｅｚｈ２を阻害するためのキノリン化合物および組成物 Active JP7768880B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020108213 2020-08-10
CNPCT/CN2020/108213 2020-08-10
PCT/CN2021/111910 WO2022033492A1 (en) 2020-08-10 2021-08-10 Quinoline compounds and compositions for inhibiting ezh2

Publications (3)

Publication Number Publication Date
JP2023538159A JP2023538159A (ja) 2023-09-07
JP2023538159A5 JP2023538159A5 (https=) 2024-08-16
JP7768880B2 true JP7768880B2 (ja) 2025-11-12

Family

ID=77520462

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022530800A Active JP7768880B2 (ja) 2020-08-10 2021-08-10 Ｅｚｈ２を阻害するためのキノリン化合物および組成物

Country Status (12)

Country Link
US (1) US12473273B2 (https=)
EP (1) EP4041725B1 (https=)
JP (1) JP7768880B2 (https=)
KR (1) KR20230051116A (https=)
CN (2) CN114555589B (https=)
AR (1) AR123185A1 (https=)
AU (1) AU2021323828A1 (https=)
CA (1) CA3180139A1 (https=)
ES (1) ES2985111T3 (https=)
IL (1) IL297332B2 (https=)
TW (1) TWI910207B (https=)
WO (1) WO2022033492A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR123185A1 (es) 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
CA3243621A1 (en) * 2022-02-01 2023-08-10 Eli Lilly And Company METHODS FOR PREPARING SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENTS
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途
CN118515653B (zh) * 2024-07-23 2024-12-10 西湖制药(杭州)有限公司 一种ezh2特异性抑制剂及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501186A (ja) 2002-07-08 2006-01-12 アストラゼネカ アクチボラグ Ｍｃｈ１ｒアンタゴニスト
JP2006124387A (ja) 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
JP2017519013A (ja) 2014-06-17 2017-07-13 ファイザー・インク 置換ジヒドロイソキノリノン化合物
CN109912576A (zh) 2019-03-20 2019-06-21 华东理工大学 环状或螺环二胺类嘧啶-异羟肟酸及其用途
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
EP1143957A3 (en) 1998-12-16 2002-02-27 Warner-Lambert Company Treatment of arthritis with mek inhibitors
JP3811775B2 (ja) 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
CN1653059A (zh) 2002-03-08 2005-08-10 卫材株式会社 用作医药品的大环化合物
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2205242B1 (en) 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US20130310379A1 (en) * 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CN110621316B (zh) * 2017-04-21 2024-01-26 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
JP7763753B2 (ja) * 2019-09-26 2025-11-04 ノバルティス アーゲー アザキノリン化合物およびその使用
AR123185A1 (es) 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501186A (ja) 2002-07-08 2006-01-12 アストラゼネカ アクチボラグ Ｍｃｈ１ｒアンタゴニスト
JP2006124387A (ja) 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
JP2017519013A (ja) 2014-06-17 2017-07-13 ファイザー・インク 置換ジヒドロイソキノリノン化合物
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
CN109912576A (zh) 2019-03-20 2019-06-21 华东理工大学 环状或螺环二胺类嘧啶-异羟肟酸及其用途

Also Published As

Publication number Publication date
JP2023538159A (ja) 2023-09-07
US20230167100A1 (en) 2023-06-01
EP4041725B1 (en) 2024-03-27
WO2022033492A1 (en) 2022-02-17
TW202220979A (zh) 2022-06-01
TWI910207B (zh) 2026-01-01
ES2985111T3 (es) 2024-11-04
IL297332B2 (en) 2026-02-01
EP4041725A1 (en) 2022-08-17
IL297332A (en) 2022-12-01
KR20230051116A (ko) 2023-04-17
US12473273B2 (en) 2025-11-18
IL297332B1 (en) 2025-10-01
AU2021323828A1 (en) 2022-05-19
CN119431341A (zh) 2025-02-14
CN114555589A (zh) 2022-05-27
CN114555589B (zh) 2024-10-25
AR123185A1 (es) 2022-11-09
CA3180139A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
JP6736559B2 (ja) トリアゾロピリミジン化合物およびその使用
JP7768880B2 (ja) Ｅｚｈ２を阻害するためのキノリン化合物および組成物
EP3472161B1 (en) Triazolopyridine compounds and uses thereof
JP7763753B2 (ja) アザキノリン化合物およびその使用
JP2019524872A (ja) 癌の治療に有用なイミダゾピリミジン化合物
HK40080941A (en) Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases
HK40080941B (en) Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases
HK40117897A (zh) 用於抑制ezh2的化合物和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240807

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250725

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251014

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251030

R150 Certificate of patent or registration of utility model

Ref document number: 7768880

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150